Unlocking Access Pharma's Value: Key Upcoming Catalysts

Mike Havrilla submits:

The stock research section of BioMedReports.com has been updated to reflect my new 19-page PDF report and update for Access Pharma (ACCP.OB) following the Company’s SEC 10Q filing for 2Q09 on 8/13/09 and my Q+A with the CEO, Jeffrey B. Davis, earlier this week.

1.) Key financial metrics include cash + equivalents as of 8/12/09 of $1.55 million (M) versus $1.23M as of 6/30/09 and $2.2M as of 3/31/09. Access continues to maintain a very low cash burn rate through 1H09, averaging about $241,000 per month or about $0.72M per quarter. In addition, Access received $1M as part of an existing licensing agreement after the end of 2Q09 with a $5.5M convertible note due 9/13/11 as the Company’s only outstanding debt.

Complete Story »